Key Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of locally advanced or metastatic
             solid tumors that have a NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alteration.

          -  Measurable disease according to RECIST version 1.1.

          -  Prior cancer therapy is allowed, including crizotinib, ceritinib, and investigational
             drugs.

          -  Prior radiotherapy is allowed

          -  Patients with controlled asymptomatic central nervous system involvement are allowed.

          -  Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer
             therapy to National Cancer Institute Common Terminology Criteria for Adverse Events
             (NCI CTCAE) Version 4.03 Grade less than or equal to 1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.

          -  Adult patients age 18 years or older.

          -  Life expectancy of at least 3 months.

        Key Exclusion Criteria:

          -  Current participation in another therapeutic clinical trial.

          -  Prior treatment with entrectinib.

          -  History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval >
             450 milliseconds).

          -  History of additional risk factors for torsade de pointes (e.g., family history of
             long QT syndrome).

          -  Known active infections (bacterial, fungal, viral including HIV positivity).

          -  Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut
             syndrome) or other malabsorption syndromes that would impact on drug absorption.

          -  Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase
             inhibitor-induced pneumonitis.

          -  Peripheral neuropathy ≥ Grade 2.